Emyria (EMD) H1 2025 earnings summary

Executive summary

• Revenue for the half-year ended 31 December 2024 was $658,199, a 40% decrease compared to the same period last year.

• Net loss after tax was $968,997, a significant improvement from the $10,793,779 loss in the prior year, primarily due to the recognition of a $1,461,770 R&D tax refund.

• Key clinical milestones achieved include promising interim results for the MDMA-assisted therapy program for PTSD and regulatory progress for the psilocybin-assisted therapy program.

• Secured $2.525M in new capital through a placement and received a $499,411 innovation grant to advance drug development.

Financial highlights

• Revenue declined 40% year-over-year to $658,199.

• Net loss after tax improved by 91% to $968,997, driven by the R&D tax refund.

• Net tangible asset per share rose to 0.31 cents from negative 3.24 cents a year ago.

• Cash and cash equivalents at period end were $1,551,069.

• No dividends were paid or declared for the period.

Outlook and guidance

• Focus remains on expanding clinical services, scaling care delivery, and advancing drug development programs.

• Plans to leverage clinical data for partnerships with health payers and to broaden access to mental health care.

• Directors are confident in the ability to raise additional funds if required and to manage costs as needed.